No Record Found
Sector
PharmaceuticalsOpen
₹71.8Prev. Close
₹71.7Turnover(Lac.)
₹5.57Day's High
₹74.39Day's Low
₹70.552 Week's High
₹133.552 Week's Low
₹37.5Book Value
₹-6.76Face Value
₹10Mkt Cap (₹ Cr.)
273.68P/E
0EPS
0Divi. Yield
025 Aug 2025
12:00 AM
Board Meeting
Agenda : Audited Result
9 Sep 2024
12:00 AM
AGM
Announcement Date: 09 Sep, 2024
No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 36.98 | 34.04 | 14.2 | 14.2 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -62.01 | -54.17 | -60.4 | -48.83 |
Net Worth | -25.03 | -20.13 | -46.2 | -34.63 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 13.71 | 20.5 | 12.86 | 8.15 |
yoy growth (%) | -33.11 | 59.34 | 57.82 | -34.37 |
Raw materials | -15.58 | -16.07 | -9.93 | -5.63 |
As % of sales | 113.6 | 78.4 | 77.17 | 69.1 |
Employee costs | -2.49 | -3.2 | -3.35 | -3.31 |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -9.92 | -3.49 | -4.47 | -5.72 |
Depreciation | -0.99 | -1.01 | -0.94 | -0.9 |
Tax paid | 0.15 | 0.23 | -0.04 | -0.08 |
Working capital | -1 | 5.04 | -2.12 | 3.97 |
Other operating items |
| Y/e 31 Mar | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -33.11 | 59.34 | 57.82 | -34.37 |
Op profit growth | 285.21 | -48.9 | -17.46 | 16.26 |
EBIT growth | 221.53 | -23.19 | -30.22 | 2.73 |
Net profit growth | 77.87 | -28.13 | -22.05 | 5.62 |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,579.6 | 76.09 | 3,78,998.95 | 753.53 | 1.01 | 5,566.68 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,164 | 70.05 | 1,63,634.83 | 557 | 0.49 | 2,357 | 561.08 |
Cipla Ltd CIPLA | 1,579 | 24.69 | 1,27,544.37 | 1,303.13 | 1.01 | 4,501.66 | 397.38 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,606.2 | 61.39 | 1,22,044.71 | 551 | 0.17 | 2,567 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,559.6 | 58.37 | 1,05,642.05 | 412.76 | 0 | 2,541.36 | 354.71 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Additional Director
Chandra Mouliswar Reddy Gangavaram
Additional Director
Balasubba Reddy Mamilla
Additional Director
Vedavathi Gangavaram
Additional Director
Sidda Reddy Kanuparthi
Additional Director
Sharvari Swapnil Shinde
Company Sec. & Compli. Officer
Ms. Kumkum Bajaj
Survey No 252/1 Aroor Village,
Sadasivapet Mandal,
Telangana - 502291
Tel: 91-08455-250080/250280
Website: http://www.oxygentapharma.com
Email: cs@ssorganics.co.in; md@ssorganics.co.in; info@sso
12-10-167,
Bharath Nagar,
Hyderbad - 500018
Tel: 91-040-23818475/76/2
Website: www.vccilindia.com
Email: info@vccilindia.com
Summary
Oxygenta Pharmaceutical Limited (Formerly known S S Organics Ltd) was incorporated as Private Limited Company in year 1990 and converted into a Limited Company in 1993, with the objective of carrying ...
Read More
Reports by Oxygenta Pharmaceutical Ltd
What is the Oxygenta Pharmaceutical Ltd share price today?
What is the Market Cap of Oxygenta Pharmaceutical Ltd?
What is the PE and PB ratio of Oxygenta Pharmaceutical Ltd?
What is the 52 Week High and Low of Oxygenta Pharmaceutical Ltd?
What is the CAGR of Oxygenta Pharmaceutical Ltd?
What is the shareholding pattern of Oxygenta Pharmaceutical Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.